Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms

作者：Torrens Gabriel; Cabot Gabriel^*; Ocampo Sosa Alain A; Conejo M Carmen; Zamorano Laura; Navarro Ferran; Pascual Alvaro; Martinez Martinez Luis; Oliver Antonio

来源：Antimicrobial Agents and Chemotherapy, 2016, 60(10): 6407-6410.

DOI：10.1128/AAC.01282-16

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at <= 4 mu g/ ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant beta-lactam resistance mechanisms.

• 出版日期2016-10